As the lesion progresses to adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma, mutations or overexpression in the epidermal growth factor receptor (EGFR) pathway also begin to show their significance.18, 19. Here, EGFR is linked to androgen insensitivity syndrome.